IHCH-8134

IHCH-8134
Identifiers
	IUPAC name (6bR,10aS)-8-(3-(2-methoxyphenyl)propyl)-1,2,6b,7,8,9,10,10a-octahydro-[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole;
PubChem CID	172549469 ;
Chemical and physical data
Formula	C23H28N2O2
Molar mass	364.489 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES [H][C@@]12[C@@](CCN(CCCC3=CC=CC=C3OC)C2)([H])N4CCOC5=C4C1=CC=C5;
	InChI InChI=InChI=1S/C23H28N2O2/c1-26-21-9-3-2-6-17(21)7-5-12-24-13-11-20-19(16-24)18-8-4-10-22-23(18)25(20)14-15-27-22/h2-4,6,8-10,19-20H,5,7,11-16H2,1H3/t19-,20-/m0/s1; Key:XIZOEKLHAJIDMD-PMACEKPBSA-N;

Last updated July 30, 2025

IHCH-8134 is a drug of the oxazinopyridoindole family which acts as an agonist at the 5-HT_2A serotonin receptor. It was derived by structural simplification of the 5-HT_2A antagonist atypical antipsychotic drug lumateperone along with several related compounds such as IHCH-7079, which was found to be a non-hallucinogenic biased 5-HT_2A agonist that was active in antidepressant assays but did not produce psychedelic-like responding in mice.^[1]^[2]^[3]

References

↑ US 6552017,Robichaud AJ, Lee T, Deng W, Mitchell IS, Yang MG, Haydar S, Chen W, Mc Clung CD, Calvello EJ, Zawrotny DM,"Substituted heterocycle fused gamma-carbolines.",issued 22 April 2003, assigned to Bristol Myers Squibb Pharma Co.
↑ US 9315504,Tomesch JC, Li P, Yao W, Zhang Q, Beard JD, Thompson AS, Cheng H, Wennogle LP,"Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof",issued 19 April 2016, assigned to Intra Cellular Therapies Inc.
↑ Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579). New York, N.Y.: 403–411. Bibcode:2022Sci...375..403C. doi:10.1126/science.abl8615. PMID 35084960. S2CID 246360313.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] US 6552017,Robichaud AJ, Lee T, Deng W, Mitchell IS, Yang MG, Haydar S, Chen W, Mc Clung CD, Calvello EJ, Zawrotny DM,"Substituted heterocycle fused gamma-carbolines.",issued 22 April 2003, assigned to Bristol Myers Squibb Pharma Co.

[2] US 9315504,Tomesch JC, Li P, Yao W, Zhang Q, Beard JD, Thompson AS, Cheng H, Wennogle LP,"Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof",issued 19 April 2016, assigned to Intra Cellular Therapies Inc.

[Cao_2022-3] Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579). New York, N.Y.: 403–411. Bibcode:2022Sci...375..403C. doi:10.1126/science.abl8615. PMID 35084960. S2CID 246360313.

[1]

[2]

[3]

Identifiers

IUPAC name (6bR,10aS)-8-(3-(2-methoxyphenyl)propyl)-1,2,6b,7,8,9,10,10a-octahydro-[1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole
PubChem CID	172549469
Chemical and physical data
Formula	C₂₃H₂₈N₂O₂
Molar mass	364.489 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES [H][C@@]12[C@@](CCN(CCCC3=CC=CC=C3OC)C2)([H])N4CCOC5=C4C1=CC=C5
InChI InChI=InChI=1S/C23H28N2O2/c1-26-21-9-3-2-6-17(21)7-5-12-24-13-11-20-19(16-24)18-8-4-10-22-23(18)25(20)14-15-27-22/h2-4,6,8-10,19-20H,5,7,11-16H2,1H3/t19-,20-/m0/s1 Key:XIZOEKLHAJIDMD-PMACEKPBSA-N

IHCH-8134

See also

References